Their goal is to find out why multiple sclerosis progresses differently from patient to patient
Google X, the lifescience division of google has joined hands with drugmaker Biogen to study environmental and biological contributors to multiple sclerosis (MS), says reports.
Using sensors, software and data analysis tools, the companies will collect and sift through data from people with the disease. Their goal is to find out why multiple sclerosis progresses differently from patient to patient.
Biogen already has five MS drugs in the market and is on a mission to use new technologies to gather round-the-clock data on patients.
The collaboration deepens Google's commitment to the health industry. Last year, Google X had collaborated with Novartis for smart contact lens project for diabetes.